MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)
This is a first-in-human trial to establish the safety, tolerability, Recommended Phase II Dose (RP2D), pharmacodynamic, and clinical activity of MK2461.
Advanced Cancer
DRUG: MK2461
To evaluate the safety and tolerability of MK2461, 18 Months
To determine the Recommend Phase II Dose or doses (RP2D) based on safety, tumor pharmacodynamics, and parmacokinetics., 18 Months
This is a first-in-human trial to establish the safety, tolerability, Recommended Phase II Dose (RP2D), pharmacodynamic, and clinical activity of MK2461.